The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...

Elizabeth Doran, a retired Canadian woman, says she has had to pick up extra teaching shifts to afford her semaglutide medication Elizabeth Doran has been taking GLP-1 medications for nearly a year ...

Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

US Supreme Court Backs Generic Drugmaker in 'Skinny Label' Patent Case By Blake Brittain WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication ...

The compiler infers, but does not take instructions. There is no syntax for explicit type declarations yet, and the new type ...

With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not ...

Our HS sports photos like the ones above put you right up close with the action and the whole experience. Check them out by clicking anywhere in the collage above to open the photo gallery. Don’t ...